Company intelligence / Profile preview
INGENIA Therapeutics
Watertown (and Boston), Massachusetts, United Statesingeniatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
IGT-427, their lead candidate for retinal diseases, is in Phase 1/2a clinical trials through a partnership. The company has developed a bispecific antibody (IGT-427) that blocks VEGF and activates Tie-2, with potential for less frequent administration and higher efficacy in treating retinal diseases.
- Therapeutic areas
- OphthalmologyOncologyImmunologyNephrology
- Modalities
- AntibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Global biotech company specializing in ophthalmic diseasesNona BiosciencesSamsung and Hana Securities (for IPO preparation)
Beyond the preview
Go deeper on INGENIA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INGENIA Therapeutics.